Office of Dr. med. Andreas Petri
- Address
- Reifferscheidstr. 2-4, 50354 Hürth, Germany
Bacterial Infections and Mycoses
At the Office of Dr. med. Andreas Petri in Hürth, pediatric research in this area focuses on preventing serious bacterial infections, especially meningococcal disease and pneumococcal disease. The trials are designed to assess how well new and existing vaccines stimulate protection in infants, toddlers, and healthy children.
- Evaluating an ACYW meningococcal vaccine for immune response and protection in young children
- Studying a 21-valent pneumococcal conjugate vaccine to improve prevention against multiple pneumococcal strains
- Assessing a pentavalent meningococcal vaccine for safety and immune response across pediatric age groups
These studies aim to strengthen pediatric immunization strategies by comparing immune responses and confirming vaccine safety in early childhood.
Virus Diseases
Clinical research in virus diseases at this site includes work on respiratory syncytial virus in infants and toddlers. The main goal is to test whether vaccination can help prevent serious lower respiratory tract illness and support better protection during the RSV season.
- Testing a respiratory syncytial virus vaccine for prevention of RSV-related lower respiratory tract disease
- Measuring vaccine effectiveness against confirmed RSV infection in young children
This research supports the development of better viral disease prevention tools for pediatric care and helps clarify how well new vaccines protect vulnerable children.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 therapeutic areas and 15 of 32 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Office of Dr. med. Andreas Petri
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Immunogenicity and Safety of Pentavalent Meningococcal ABCYW Vaccine in Pediatric Populations Compared to Licensed Meningococcal Vaccines | Sanofi Pasteur Inc. | Phase II | Not Recruiting | Mar 2025 | — |
IMP list
lock Showing 1 of 32 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated) Conjugated To Tetanus Toxoid | 2 | Unknown | 2024-03-12 | 2025-03-10 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.